Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline-filled breast implant sizers to identify the correct style and size of implants; and non-breast tissue expanders for expanding tissue and skin surface area for burn care and other reconstructive use. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SIEN
CUSIPN/A
Phone805-562-3500
Debt
Debt-to-Equity Ratio0.27
Current Ratio3.06
Quick Ratio2.63
Price-To-Earnings
Trailing P/E Ratio-8.63
Forward P/E Ratio-8.30
P/E GrowthN/A
Sales & Book Value
Annual Sales$36.54 million
Price / Sales18.93
Cash FlowN/A
Price / CashN/A
Book Value$1.42 per share
Price / Book17.13
Profitability
EPS (Most Recent Fiscal Year)($2.82)
Net Income$-64,020,000.00
Net Margins-131.16%
Return on Equity-151.47%
Return on Assets-58.22%
Miscellaneous
Employees200
Outstanding Shares28,430,000
Market Cap$691.65 million
Sientra (NASDAQ:SIEN) Frequently Asked Questions
What is Sientra's stock symbol?
Sientra trades on the NASDAQ under the ticker symbol "SIEN."
How were Sientra's earnings last quarter?
Sientra Inc (NASDAQ:SIEN) announced its quarterly earnings results on Tuesday, August, 7th. The medical instruments supplier reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.69) by $0.04. The medical instruments supplier had revenue of $17.55 million for the quarter, compared to the consensus estimate of $15.30 million. Sientra had a negative net margin of 131.16% and a negative return on equity of 151.47%. View Sientra's Earnings History.
When is Sientra's next earnings date?
What price target have analysts set for SIEN?
9 brokers have issued 1-year price targets for Sientra's shares. Their forecasts range from $16.00 to $31.00. On average, they expect Sientra's stock price to reach $24.1429 in the next year. This suggests that the stock has a possible downside of 0.8%. View Analyst Price Targets for Sientra.
What is the consensus analysts' recommendation for Sientra?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sientra.
What are Wall Street analysts saying about Sientra stock?
Here are some recent quotes from research analysts about Sientra stock:
- 1. According to Zacks Investment Research, "Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra's primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. " (9/21/2018)
- 2. Canaccord Genuity analysts commented, "We reiterate our BUY rating on Sientra following strong Q1/18 results that came in slightly ahead of prelim results. SIEN has had a busy start to the year executing on key initiatives that leave us incrementally more confident in the company’s ability to deliver upside to estimates moving forward. Specifically, SIEN received FDA approval of the company’s new manufacturing facility and immediately re-entered the US breast implant market early in the Q2, posted a robust Q1 that showed continued momentum in tissue expander sales as well as encouraging signs of a turnaround in the miraDry business, and lastly completed a $108M (net of fees) capital raise." (5/10/2018)
Who are some of Sientra's key competitors?
Some companies that are related to Sientra include Halyard Health (HYH), CONSORT Med PLC/S (CSRMY), Establishment Labs (ESTA), Invacare (IVC), RTI Surgical (RTIX), Lakeland Industries (LAKE), ConforMIS (CFMS), Rewalk Robotics (RWLK), Histogenics (HSGX), Bionik Laboratories (BNKL), COLLPLANT HOLDI/S (CLGN), NanoVibronix (NAOV), Precision Therapeutics (AIPT), Allied Healthcare Products (AHPI) and Avitar (AVTI).
Who are Sientra's key executives?
Sientra's management team includes the folowing people:
- Mr. Jeffrey M. Nugent, Chairman & CEO (Age 71)
- Mr. Charles Huiner, COO and Sr. VP of Corp. Devel. & Strategy (Age 47)
- Mr. Patrick F. Williams, Sr. VP & GM of miraDry (Age 45)
- Mr. Keith J. Sullivan, Director & Advisor (Age 60)
- Mr. Paul Sean Little, CFO, Sr. VP & Treasurer (Age 53)
Who are Sientra's major shareholders?
Sientra's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.29%), Gilder Gagnon Howe & Co. LLC (4.87%), Janus Henderson Group PLC (3.71%), Millennium Management LLC (3.02%), Waddell & Reed Financial Inc. (2.71%) and Columbus Circle Investors (1.55%). Company insiders that own Sientra stock include Jeffrey M Nugent, Patrick F Williams, R Scott Greer and Timothy Haines. View Institutional Ownership Trends for Sientra.
Which institutional investors are selling Sientra stock?
Which institutional investors are buying Sientra stock?
SIEN stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Waddell & Reed Financial Inc., BlackRock Inc., Columbus Circle Investors, Millennium Management LLC, Cortina Asset Management LLC, Gilder Gagnon Howe & Co. LLC and Granahan Investment Management Inc. MA. Company insiders that have bought Sientra stock in the last two years include Jeffrey M Nugent, Patrick F Williams, R Scott Greer and Timothy Haines. View Insider Buying and Selling for Sientra.
How do I buy shares of Sientra?
Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sientra's stock price today?
One share of SIEN stock can currently be purchased for approximately $24.33.
How big of a company is Sientra?
Sientra has a market capitalization of $691.65 million and generates $36.54 million in revenue each year. The medical instruments supplier earns $-64,020,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis. Sientra employs 200 workers across the globe.
What is Sientra's official website?
How can I contact Sientra?
Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at 805-562-3500 or via email at [email protected]
MarketBeat Community Rating for Sientra (NASDAQ SIEN)
MarketBeat's community ratings are surveys of what our community members think about Sientra and other stocks. Vote "Outperform" if you believe SIEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SIEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
